NCT04223635View on ClinicalTrials.gov

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

January 7, 2020

Primary Completion Date

October 2, 2020

Study Completion Date

October 2, 2020

Conditions
Moderate Hepatic Impairment
Interventions
DRUG

Pexidartinib

Single, 200-mg capsule will be administered orally on Day 1 with 240 mL of water, following an overnight fast of at least 10 hours.

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014-3616

Clinical Pharmacology of Miami, LLC., Miami

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT04223635 - Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants | Biotech Hunter | Biotech Hunter